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Fracture Risk Assessment in Atypical
Parkinsonian Syndromes
Christopher Kobylecki, FRCP, PhD,1,2,* Hannah Glasse, MB, ChB,1 Jigisha Amin, MB, ChB,3 Celia L. Gregson, FRCP, PhD,4
Veronica Lyell, FRCP,5 and Emily J. Henderson, FRCP, PhD5,6
ABSTRACT: Background: Bone health and fracture risk reduction are increasingly recognized as important
issues in Parkinson’s disease (PD). However, the evidence for fracture risk management in atypical
parkinsonism (AP) is less clear. Guidance on management of bone health in PD has recently been published.
Objectives: To evaluate the outcome of fracture risk assessment in a cohort of patients with AP, compared to a
population with idiopathic PD.
Methods: We did a cross-sectional study of patients with PD or AP who had fracture risk assessed at two
tertiary movement disorder centres. Data on fracture risk as assessed using QFracture and FRAX were
collected. To assess for the effect of age on fracture risk we compared the risks of PD and AP patients aged
≤70 and >70 years.
Results: We assessed 71 patients with AP and 267 with PD. Age, sex and body mass index were similar between
groups; patients with AP were more likely to have fallen in the previous year. Major osteoporotic fracture risk
was greater in patients with AP aged ≤70 compared to PD; no differences between groups were seen in those
aged >70 years. 76% of those with AP, and 63% with PD, had an estimated fracture risk indicating bone-sparing
treatment, but only 33% of patients with AP were receiving this where it was indicated.
Conclusion: There is scope for considerable improvement in fracture risk assessment and treatment in atypical
parkinsonism, taking into account the worse prognosis of this patient group.
The importance of considering fracture risk and maintaining bone
health is an increasingly recognized issue in people with Parkinson’s
disease (PD). People with PD have a greater than two-fold risk of
osteoporotic fracture than age-matched healthy controls; this is par-
ticularly so in men with PD who have an almost three-fold
increased risk.1,2 Multiple factors contribute to this increased risk,
including increased risk of falling, vitamin D deficiency, reduced
physical activity and impaired nutrition.3 Atypical parkinsonian syn-
dromes such as multiple system atrophy (MSA) and progressive
supranuclear palsy (PSP) are more rapidly progressive than PD,
exhibit a poor response to dopaminergic therapy and are associated
with a reduced latency to falling and a high incidence of fractures.4
Given the potential for increased risk of fractures in patients
with atypical parkinsonism (AP), there is relatively little
supporting literature or disease-specific evidence base regarding
management of bone health in these conditions. Whilst one pro-
spective cohort study failed to identify an increased risk of frac-
tures in AP compared to PD, these findings may have been
explained by the reduced mobility and therefore reduced risk of
falling that may occur with advanced AP.5 Yarnall and colleagues
identified previous fractures in one quarter of their outpatient
clinic population (29 PSP, 7 MSA), despite which only two of
these patients were currently on bone protection.6 Fracture risk
appears to be an under-appreciated issue in patients with AP.
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Since these earlier papers, guidance on assessment and treat-
ment of fracture risk in parkinsonian syndromes has been publi-
shed.3 This guidance suggested the use of QFracture7 to assess
10-year risk of major osteoporotic fracture, with a threshold of
major osteoporotic fracture (MOF) risk ≥20% and/or neck of
femur fracture (NOF) risk ≥5% to trigger empirical bone
TABLE 1 Risk factors, treatments and calculated fracture risks for patients with Parkinson’s disease and atypical Parkinsonism
Atypical Parkinsonism groups
PD n = 267 Atypical Parkinsonism n = 71 MSA n = 21 PSP n = 31 CBS n = 12 DLB n = 7













BMI 26.2 (5.8) 25.7 (6.0) 25.6 (8.0) 24.9 (6.0) 24.9 (3.9) 28.5 (4.1)
Previous fragility fracture (%) 47 (17.6) 13 (18.3) 5 (23.8) 6 (19.3) 2 (16.7) 0 (0)
Parental hip fracture (%) 21 (7.9) 9 (12.7) 4 (19.0) 5 (16.1) 3 (25) 0 (0)
Fall in the last year (%) 110 (41.1) 53 (74.6)*** 17 (81.0) 26 (83.9) 5 (41.7) 5 (71.4)
Vitamin D supplement (%) 135 (50.6) 41 (57.7) 13 (61.9) 16 (51.6) 7 (58.3) 5 (71.4)
Calcium supplement (%) 102 (38.2) 40 (56.3)** 13 (61.9) 15 (48.3) 7 (58.3) 5 (71.4)
Prescribed oral bisphosphonate (%) 42 (15.7) 18 (25.4) 3 (14.2) 9 (29.0) 4 (33.3) 2 (28.6)
PD, idiopathic PD; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBS, corticobasal syndrome; DLB, dementia with Lewy
Bodies. BMI, body mass index. Data presented as mean (SD), number (%) or median (IQR).
**P < 0.01,
***P < 0.001 compared to PD (Chi-squared test).
FIG. 1. Fracture risks in atypical parkinsonian syndromes and idiopathic Parkinson’s disease as assessed by QFracture in those aged >70
(A) and ≤70 years (B). FRAX assessement is shown in those aged >70 (C) and ≤70 years (D). Bars represent median 10-year fracture
risk ± interquartile range. NOF, neck of femur. Statistical comparisons made using Mann–Whitney U test.
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protection treatment.3 Our aim was to evaluate the outcome of
fracture risk assessment and subsequent management in patients
with AP as part of a clinical service review, and compare findings
to a population of patients with idiopathic PD.
Methods
We conducted a cross-sectional study of patients with atypical
parkinsonism and idiopathic PD who were assessed at one of
two specialist movement disorder clinics in Salford Royal NHS
Foundation Trust and Royal United Hospitals Bath NHS Trust
by specialists in movement disorders and/ or bone health. We
included all patients with these diagnoses assessed between
December 2015–December 2016. Demographic data and infor-
mation on risk factors for fracture were collected directly from
medical records into a custom-built database (Microsoft Excel).
Information on treatments for bone health (calcium, vitamin D,
bisphosphonates, denosumab) at the time or immediately follow-
ing the consultation were also recorded. Patients were weighed
and height measured; BMI was calculated as weight (kg)/height
(m2). The 10 year risks of hip and major osteoporotic fracture
were calculated using QFracture7 and FRAX.8
Continuous data were compared between PD and AP using
the student’s t test if normally distributed or the Mann–Whitney
U test if not normally distributed. Categorical variables were
compared using the Chi-squared test. To determine to what
extent fracture risk differed by age, we stratified our study popu-
lation as >70 or ≤70 years, using this cutoff as patients under
70 are often considered “young” in a movement disorders setting
and may be presumed to be at lower risk of fracture. Statistical
analysis was undertaken using SPSS 23.0 (IBM).
Results
We analyzed a total of 71 patients with AP (21 MSA, 31 PSP,
12 corticobasal syndrome, 7 dementia with Lewy Bodies) and
267 with idiopathic PD. Demographic details are shown in
Table 1. The AP and PD groups were similar in terms of age, sex
and BMI. The proportion of patients reporting a prior fracture or
a parental history of fracture did not differ between groups.
Patients with AP were more likely to have fallen within the last
year, than patients with PD (53/71 [74.6%] vs. 110/267 [41.1%],
P < 0.001). Full information on components of QFracture and
FRAX assessments is provided in supplementary Table S1.
The 10-year risks of major osteoporotic fracture (MOF), as
calculated by QFracture and FRAX, were similar in the total
population of patients with AP and PD and those aged >70 years
(Fig. 1A,C). However, when we examined patients ≤70 years
old, major osteoporotic fracture risk assessed using QFracture was
greater in those with AP (n = 25, median 11.7% [IQR 5–19])
compared to those with PD (n = 73, median 4.7% [2-10],
P < 0.001). The risk of hip fracture was also three-fold higher in
patients with AP aged ≤70 years old (median 5.1% [2–8])
compared to those with PD (median 1.5% [1–3], P < 0.001;
Fig. 1B). When FRAX was used to calculate the 10-year proba-
bility of hip and major osteoporotic fractures, similar patterns
were seen (Fig. 1D). There were no differences in sex or BMI
between patients with AP and PD in either age group, although
falls remained more prevalent in AP in both age categories. Frac-
ture risks for individual atypical parkinsonian syndromes are
shown in Fig. 2. There were no significant differences in fracture
risk when comparing individual AP syndromes to others.
A total of 54 patients with AP (76%), and 167 (63%) patients
with PD had a QFracture MOF risk ≥20% and/or hip fracture
risk ≥5%, fulfilling criteria for bone-sparing treatment. Despite
these risks, no differences were seen in the proportion of patients
receiving vitamin D or calcium supplementation or oral bis-
phosphonate therapy, by fracture risk. Only 18 (33%) patients
with AP, in whom bisphosphonates were potentially indicated,
were receiving this therapy, whereas 35 (65%) were taking vita-
min D and calcium supplements. One patient with PD and one
with AP received parenteral bisphosphonate therapy; one patient
with PD received denosumab therapy. Bone densitometry had
been performed in 7 of the AP group (10%) and 39 (15%) of PD
patients.
FIG. 2. Fracture risks in individual atypical parkinsonian
syndromes assessed by QFracture (A) and FRAX (B). Bars
represent median 10-year fracture risk ± interquartile range.
MOF, major osteoporotic fracture; NOF, neck of femur; MSA,
multiple system atrophy; PSP, progressive supranuclear palsy;
CBS, corticobasal syndrome; DLB, dementia with Lewy bodies.
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Discussion
To our knowledge this is the largest report of clinical fracture
risk assessment and bone health treatment in patients with atypi-
cal parkinsonism. Comparing the risk factors for future fracture
between groups, our data indicate that previous fractures had
occurred in 18% of both our AP and PD populations. The main
difference between the two populations, was the much higher
incidence of falls in patients with AP, consistent with the previ-
ous literature.4 Whereas there were no differences in estimated
fracture risk overall, both major osteoporotic fracture and hip
fracture risks were higher in younger (aged ≤70 years) patients
with atypical parkinsonian syndromes compared to those with
PD, which reinforces the importance of evaluating fracture risk
in a comparatively younger population. The proportionately
greater contribution of advancing age to fracture risk in the older
group is likely to explain this discrepancy, whereas a higher level
of other risks such as falls in the younger AP group is likely to
drive the greater risk seen in this group. Greater differences are
seen in assessment of MOF compared to hip fracture,9 consistent
with our data.
PD and AP are established risk factors for fragility fracture. In
2017, the UK National Institute for Health and Care Excellence
clearly stated that fracture risk assessment should be considered in
all men and women with a risk factor for fracture.10 Thus, all
men and women with PD and AP in the UK should routinely
be assessed for fracture risk.10 Recent guidance on fracture risk
assessment specifically in parkinsonism suggests the use of
QFracture in life-limiting conditions when prognosis is <10 years,
as opposed to a recommendation to use FRAX in PD assessment
where quantification of 10-year fracture risk has greater clinical
utility.11 Given the evidence of more rapid progression in MSA
and PSP compared to PD, with a mean life expectancy from diag-
nosis of 7–8 years,12 this would support the use of QFracture in
the first instance. QFracture as a tool is able to calculate risk over
shorter time periods (from 1 to 10 years at one yearly increments)
and incorporates more risk factors in the calculation including
whether or not the patient has PD and experienced a fall. Falls
have been identified as a risk for fractures independently of
FRAX-derived fracture probabilities,13 which emphasizes their
importance in patients with atypical parkinsonism, where falls
occur more frequently. The inclusion of falls in the QFracture
algorithm is a potential strength in this regard; FRAX calculations
make no distinction on the basis of falls.
Despite appropriate fracture risk assessment in our population
with AP, the proportion treated with bone-sparing therapy was
lower than expected. The reasons for this could include poor
tolerability and adherence to oral bisphosphonate therapy, as well
as a lack of awareness of current guidance by clinicians.11 Dys-
phagia may well contribute to poor adherence given the difficul-
ties with swallowing oral bisphosphonates, highlighting the
potential role of parenteral bone-sparing therapies in this popula-
tion. However, our data and clinical experience suggests that
parenteral treatments seem under utilized. This may be due to
the lack of familiarity with using parenteral drugs, concern about
potential side effects, access to services, and under-recognition of
fall and fracture risk in this population.
We acknowledge limitations to our work, including the fact
that risk assessment may not be representative of generalist
clinics without a special interest in bone health, and the lack of
follow-up data to determine long-term adherence or outcomes
from bone-sparing therapy. Specifically, we do not have data
on the rates of further falls or fractures in this population, and
the study is not powered to detect the effects of such interven-
tions. Further prospective work to assess real-world fracture
risk following assessment, and the efficacy of bone-sparing
measures in such populations would be valuable. In particular,
fracture risk may differ in subtypes of PSP such as PSP-parkin-
sonism, given the longer latency to falls in this condition 4 as
well as between the different AP conditions. Bone-sparing
therapy may not be appropriate when the last year of life is
reached, and our data do not explicitly identify those where
treatment was considered and then appropriately withheld. It is
possible that more widespread bone densitometry measurement
would have yielded more precise evaluation of fracture risk,
although such measurement is not currently recommended in
all parkinsonian patients.11 Finally, we cannot identify the
number in our population who went on to have further frac-
tures, given that predicted fracture risk may not equate to real-
life risk. Strengths of our study include recruitment from two
specialist centres with expertise in movement disorders and
bone health, a standardized data collection method and a com-
parative group of patients with PD.
In conclusion, there remains substantial scope for improve-
ment in ascertainment of fracture risk and incidence and the
implementation of evidence-based therapy to reduce fracture risk
in patients with atypical parkinsonism. Current guidance for the
use of QFracture in this patient group with fracture risk calcu-
lated for a shorter (eg 5 year) time period would accommodate
reduced life expectancy whilst identifying those at risk of the
serious and life-threatening complication of osteoporotic frac-
ture.11 Widespread, routine roll-out of this method would help
to improve fracture risk assessment in people with atypical par-
kinsonian syndromes and inform shared-decision making in risk
management for their remaining years of life.
Author Roles
(1) Research Project: A. Conception, B. Organization,
C. Execution; (2) Statistical Analysis: A. Design, B. Execution,
C. Review and Critique; (3) Manuscript Preparation: A. Writing
of the first draft, B. Review and Critique.
C.K.: 1A, 1B, 2A, 2B, 2C, 3A, 3B
H.G.: 1B, 1C, 2C, 3B
J.A.: 1B, 1C, 3B
C.L.G.: 1A, 1B, 2C, 3B
V.L.: 1A, 1B, 1C, 3B
E.J.H.: 1A, 1B, 2C, 3B
388 MOVEMENT DISORDERS CLINICAL PRACTICE 2021; 8(3): 385–389. doi: 10.1002/mdc3.13146
RESEARCH ARTICLE FRACTURE RISK IN ATYPICAL PARKINSONISM
Disclosures
Ethical Compliance Statement: As this was a quality
improvement project, we confirm that approval of an institu-
tional review board was not required for this work and informed
patient consent was not required. We confirm that we have read
the Journal’s position on issues involved in ethical publication
and affirm that this work is consistent with those guidelines.
Funding Sources and Conflicts of Interest: No specific
funding was received for this work, and the authors declare no
conflict of interest.
Financial Disclosures for the Previous 12 Months:
Christopher Kobylecki has received grants from Parkinson’s UK
and the Michael J Fox Foundation; speaker fees from Britannia
and Bial Pharma; support to attend international meetings from
Abbvie. Hannah Glasse, Jigisha Amin, Celia L Gregson, report
no financial disclosures. Veronica Lyell has received fees for work
on educational material from Parkinson’s UK. Emily J Hender-
son has received research funding from the National Institute of
Health Research (NIHR), Parkinson’s-UK, the Gatsby Founda-
tion. She has received travel, consultancy, and honoraria from
Profile Pharma, Bial, Abbvie, and Ever pharma. ■
References
1. Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R,
Lees AJ. Bone health in Parkinson’s disease: a systematic review and
meta-analysis. J Neurol Neurosurg Psychiatry 2014;85:1159–1166.
2. Schini M, Vilaca T, Poku E, et al. The risk of hip and non-vertebral
fractures in patients with Parkinson’s disease and parkinsonism: a system-
atic review and meta-analysis. Bone 2020;132:115173.
3. Lyell V, Henderson E, Devine M, Gregson C. Assessment and manage-
ment of fracture risk in patients with Parkinson’s disease. Age Ageing
2015;44:34–41.
4. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in
bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg
Psychiatry 2006;77:468–473.
5. Sleeman I, Che ZC, Counsell C. Risk of fracture amongst patients with
Parkinson’s disease and other forms of parkinsonism. Parkinsonism Relat
Disord 2016;29:60–65.
6. Yarnall AJ, Duncan GW, Khoo TK, Burn DJ. Falling short: underesti-
mation of fracture risk in atypical parkinsonian syndromes. Parkinsonism
Relat Disord 2012;18:692–693.
7. Hippisley-Cox J, Coupland C. Derivation and validation of updated
QFracture algorithm to predict risk of osteoporotic fracture in primary
care in the United Kingdom: prospective open cohort study. BMJ 2012;
344:e3427.
8. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and
the assessment of fracture probability in men and women from the UK.
Osteoporos Int 2008;19:385–397.
9. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and
hip fracture in the United Kingdom: prospective independent and exter-
nal validation of QFractureScores. BMJ 2011;342:d3651.
10. National Institute for Health and Care Excellence. Osteoporosis:
assessing the risk of fragility fracture: clinical guideline [CG146]. 2017.
11. Henderson EJ, Lyell V, Bhimjiyani A, Amin J, Kobylecki C,
Gregson CL. Management of fracture risk in Parkinson’s: a revised algo-
rithm and focused review of treatments. Parkinsonism Relat Disord 2019;
64:181–187.
12. O’Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of pro-
gressive supranuclear palsy and multiple system atrophy. Brain 2008;131:
1362–1372.
13. Harvey NC, Oden A, Orwoll E, et al. Falls predict fractures indepen-
dently of FRAX probability: a meta-analysis of the osteoporotic fractures
in men (MrOS) study. J Bone Miner Res 2018;33:510–516.
Supporting Information
Supporting information may be found in the online version of
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Table S1. Additional features contributing to fracture risk
assessment in patients with Parkinson’s disease and atypical par-
kinsonism as assessed by QFracture and FRAX.
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